Hosted on MSN1d
Outlook Therapeutics Secures Funding and Board Restructures
Outlook Therapeutics ( ($OTLK) ) has provided an update. On January 31, 2025, Outlook Therapeutics entered into a Securities Purchase Agreement ...
Ed Arce’s Buy Rating on Arcturus Therapeutics Driven by Strategic Advancements and Strong Market Positioning
In a report released today, Ed Arce from H.C. Wainwright maintained a Buy rating on Arcturus Therapeutics (ARCT – Research Report), with a ...
PFG Investments LLC Grows Stake in CRISPR Therapeutics AG (NASDAQ:CRSP)
PFG Investments LLC lifted its stake in CRISPR Therapeutics AG (NASDAQ:CRSP – Free Report) by 9.9% in the 4th quarter, ...
Corcept Therapeutics Incorporated (NASDAQ:CORT) Receives $65.25 Consensus PT from Analysts
Corcept Therapeutics Incorporated (NASDAQ:CORT – Get Free Report) has earned an average recommendation of “Buy” from the five ratings firms that are covering the company, Marketbeat reports. Five ...
Atossa Therapeutics: Strong Strategic Positioning and Patent Resilience Justifies Buy Rating
Atossa Therapeutics (ATOS – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Emily Bodnar ...
TipRanks on MSN2d
Alterity Therapeutics announces ATH434 Phase 2 trial results
Alterity Therapeutics (ATHE) announced topline results from the ATH434-201 randomized, double-blind, placebo-controlled Phase 2 clinical trial in ...
Osta Therapeutics Strengthens Leadership Team with Two Industry Experts Supporting its Goal of Addressing Antibiotic Resistance
Osta Therapeutics, a biotechnology company developing smart drugs to fight antibiotic resistance, today announced the appointments of Dr. Gilles Courtemanche as Senior Scientific Advisor and Dr.
From Underperformance To Opportunity: Biotech's Case For 2025
Despite continued underperformance in 2024, the biotech sector enters 2025 with a brighter outlook driven by groundbreaking ...